

Resource Summary Report

Generated by RRID on Sep 8, 2026

p53 (D2H9O) (Rodent Specific)

RRID:AB_2757821

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 32532, RRID:AB_2757821

Antibody Information

URL: http://antibodyregistry.org/AB_2757821

Proper Citation: Cell Signaling Technology Cat# 32532, RRID:AB_2757821

Target Antigen: p53

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, ChIP

Antibody Name: p53 (D2H9O) (Rodent Specific)

Description: This monoclonal targets p53

Target Organism: rat, mouse

Clone ID: D2H9O

Antibody ID: AB_2757821

Vendor: Cell Signaling Technology

Catalog Number: 32532

Record Creation Time: 20231110T033306+0000

Record Last Update: 20260901T004535+0000

Ratings and Alerts

No rating or validation information has been found for p53 (D2H9O) (Rodent Specific).

No alerts have been found for p53 (D2H9O) (Rodent Specific).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Braun LM, et al. (2025) Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. *Cancer cell*, 43(2), 269.

Wang NB, et al. (2025) Compact transcription factor cassettes generate functional, engraftable motor neurons by direct conversion. *Cell systems*, 16(4), 101206.

Windley SP, et al. (2025) NEDD4 Promotes Sertoli Cell Proliferation and Adult Leydig Cell Differentiation in the Murine Testis. *Endocrinology*, 166(9).

Yang X, et al. (2025) Berberine Protects Pancreatic β -Cells From IL-1 β Damage Through Hormetic Mechanisms Via P53-Mediated Apoptosis Pathways. *Endocrinology*, 166(9).

Lende-Dorn BA, et al. (2025) Chemogenetic tuning reveals optimal MAPK signaling for cell-fate programming. *Cell reports*, 44(9), 116226.

Cui J, et al. (2025) Peach Gum Polysaccharide Prevents Chemotherapy-Induced Intestinal Injury and Degenerative Behavior. *Integrative cancer therapies*, 24, 15347354251368410.

Huber A, et al. (2024) Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines. *Cell reports*, 43(8), 114616.

Ulfig A, et al. (2024) Redox heterogeneity in mouse embryonic stem cells individualizes cell fate decisions. *Developmental cell*, 59(16), 2118.

LaBella KA, et al. (2024) Telomere dysfunction alters intestinal stem cell dynamics to promote cancer. *Developmental cell*, 59(11), 1475.

Pan Y, et al. (2023) KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition. *Cancer cell*, 41(1), 88.

Ruan GX, et al. (2022) The spliceosome component Usp39 controls B cell development by regulating immunoglobulin gene rearrangement. *Cell reports*, 38(6), 110338.

Li Q, et al. (2020) p53 Integrates Temporal WDR5 Inputs during Neuroectoderm and Mesoderm Differentiation of Mouse Embryonic Stem Cells. *Cell reports*, 30(2), 465.

Lowman XH, et al. (2019) p53 Promotes Cancer Cell Adaptation to Glutamine Deprivation by Upregulating Slc7a3 to Increase Arginine Uptake. *Cell reports*, 26(11), 3051.